INDC 2020, Congress Centre Masarykova kolej, Prague, Nov 29 – Dec 02, 2020 INDC is an international forum for a scientific discussion focused on the understanding the relationship between nutrition and clinical diagnostics. […]readmore
Shots: The TGA authorization follows the recent data shared by EMA and Singapore Health Sciences Authority for remdesivir’s approval in EU, Singapore and, Japan for COVID-19 patients TGA’s approval was […]readmore
Shots: The designation is based on preliminary data from P-I/II study assessing BNT162b1 including animal immunogenicity studies results that were released on Jul 01, 2020. Additionally, the early results of […]readmore
Shots: Samsung Biologics to offer CDO services from cell line development, process development, non-clinical & clinical material manufacturing, to IND submission for global clinical trials of STM418 The companies have […]readmore
Shots: The P-III IMagyn050 study involves assessing of Tecentriq + Avastin, paclitaxel, and carboplatin vs PBO + Avastin, paclitaxel and carboplatin in the ratio (1:1) in women with Stage III or […]readmore
Shots: The approval is based on the positive outcomes of a clinical trial assessing Itolizumab for its safety and efficacy in preventing CRS in moderate to severe ARDS patients due […]readmore
1. LEO Reports the US FDA’s Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis Published Date: Jul 10, 2020 | Tags: LEO, Reports, US, […]readmore
The approval is based on P-III trial assessing Upneeq vs PBO in 2:1 ratio in 140 patients with acquired blepharoptosis split into two treatment groups for 42 days. Additionally, another […]readmore
Shots: The MAA validation is based on P-II DESTINY-Breast01 trial assessing Trastuzumab Deruxtecan as a monothx in patients with 2L+ HER2 positive metastatic breast cancer and the results were published […]readmore
Shots: The approval is based on P-III IRIDIUM study assessing Enerzair Breezhaler (qd) vs Atectura Breezhaler (QMF149; IND/MF) in 3092 patients in the ratio (1:1:1:1) whose asthma is uncontrolled with […]readmore